DURECT (NASDAQ:DRRX) Rating Increased to Buy at BidaskClub

DURECT (NASDAQ:DRRX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday, BidAskClub reports.

Several other research firms have also recently issued reports on DRRX. Cantor Fitzgerald initiated coverage on DURECT in a report on Monday, November 18th. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright set a $3.50 price target on DURECT and gave the company a “buy” rating in a report on Wednesday, September 18th. ValuEngine cut DURECT from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Stifel Nicolaus raised their price target on DURECT from $1.50 to $2.10 and gave the company a “hold” rating in a report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $3.53.

Shares of DRRX stock opened at $2.19 on Tuesday. The stock’s fifty day moving average is $1.92 and its 200-day moving average is $1.35. The stock has a market capitalization of $409.73 million, a PE ratio of -13.69 and a beta of 1.75. DURECT has a 52 week low of $0.46 and a 52 week high of $2.46. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.72 and a current ratio of 1.81.

DURECT (NASDAQ:DRRX) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). The firm had revenue of $10.76 million during the quarter, compared to the consensus estimate of $7.78 million. DURECT had a negative net margin of 105.07% and a negative return on equity of 119.34%. As a group, analysts forecast that DURECT will post -0.11 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Goelzer Investment Management Inc. bought a new position in DURECT in the second quarter valued at about $26,000. Tower Research Capital LLC TRC boosted its holdings in DURECT by 51.8% during the second quarter. Tower Research Capital LLC TRC now owns 60,829 shares of the specialty pharmaceutical company’s stock worth $40,000 after buying an additional 20,764 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in DURECT by 36.9% during the third quarter. Commonwealth Equity Services LLC now owns 25,955 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 7,000 shares during the last quarter. Squarepoint Ops LLC bought a new position in DURECT during the third quarter worth about $55,000. Finally, Morgan Stanley boosted its holdings in DURECT by 319.8% during the second quarter. Morgan Stanley now owns 166,748 shares of the specialty pharmaceutical company’s stock worth $109,000 after buying an additional 127,028 shares during the last quarter. Institutional investors and hedge funds own 30.08% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.

Read More: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.